Always good to have friends in the legal profession. I know a fee in both professions. It’s remarkable how hard it is to get HF’s to take a look at a pre-revenue biotech on the OTC. Too many big cap opportunities right now. Not worth the risk for them at this time. A few of them have small private investments in NWBO, but they are too disciplined to jump in big time at this time. They will get involved when NWBO gets approved….hopefully.